Date: 2015-07-22
Type of information: Private placement
Company: Txcell (France)
Investors:
Amount: € 8 million
Funding type: private placement
Planned used: The proceeds from the placement will be used as additional means for financing of:
- ongoing or coming clinical developments (Ovasave®, Col-Treg), preclinical & R&D developments
- acceleration of R&D activities, notably on CAR-Treg platform
- process and manufacturing development of ASTrIA platform
- running and structure costs of the company.
Others: * On July 22, 2015, TxCell, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announced the successful completion of a private placement of a total amount of approximately € 8 million. Stéphane Boissel, CEO of TxCell, subscribed 20,000 new shares, representing approximately 1.71 percent of the private placement. A total of 1,116,300 new shares have been issued by means of a capital increase without shareholders preemptive rights pursuant to the 14th resolution of the TxCell shareholders’ meeting of May 26, 2015. The new shares represent around 9.95 percent of the outstanding shares prior to the private placement. The private placement was conducted by way of an accelerated book building in accordance with article L. 411-2 II of the French Monetary and Financial Code (code monétaire et financier). Pursuant to the 16th resolution of the company’s ordinary and extraordinary shareholders general meeting dated May 26, 2015 the issue price has been set at € 6.80 per share, representing a discount of 8.48 percent compared to the weighted average stock price over the past three trading sessions, which was € 7.43. In total, approximately 70 percent of the operation was placed internationally - outside France. An application will be made to list the new shares on the regulated market of Euronext in Paris (“Euronext Paris”). The new shares will be listed under the same code as the existing shares (ISIN FR0010127662). The new shares shall carry dividends rights as from their issue date and be immediately fungible in all respects with the company’s existing shares. The settlement and delivery should occur on July 24, 2015.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Digestive diseases - Ophtalmological diseases
